BAY 79-4980: Phase I start

BAYG submitted an IND to begin in 3Q05 a double-blind, U.S. Phase I trial in 32 patients to compare BAY 79-4980, a longer-acting formulation of Kogenate, to the currently marketed Kogenate FS. BAYG ...